Table 7.
Levels of UA and UA/Cr ratio between severe and moderate symptoms and three time points by gender
| Fixed Effects | UA | UA/Cr ratio | ||||||
|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||||
| Effect Size | 95% CI | Effect Size | 95% CI | Effect Size | 95% CI | Effect Size | 95% CI | |
| Moderate | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| Severe | −0.17 | (− 0.29, − 0.05) | 0.07 | (−0.11, 0.24) | − 0.19 | (− 0.35, − 0.04) | 0.02 | (−0.15, 0.19) |
| Admission | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| Discharge | −0.05 | (−0.12, 0.01) | −0.11 | (− 0.18, − 0.04) | −0.06 | (− 0.14, 0.01) | −0.18 | (− 0.25, − 0.12) |
| Follow-up | 0.04 | (− 0.04, 0.13) | 0.04 | (− 0.03, 0.11) | 0.05 | (− 0.04, 0.14) | −0.03 | (− 0.10, 0.04) |
Note: Linear mixed effects models were used to assess changes of levels of UA and UA/Cr ratio between severe and moderate symptoms and three time points by gender
Abbreviations: UA Uric acid, Cr Creatinine